SCHEMBL975510

SCHEMBL975510

[O]Cc1cc2cccc3ccc4cccc1c4c32

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.52
ERBB2 P04626 1/20 0.52
FYN P06241 1/20 0.52
MAOA P21397 1/20 0.52
ACHE P22303 1/20 0.52
AHR P35869 1/20 0.52
ALDH1A1 P00352 6/20 0.46
HPGD P15428 5/20 0.46
HSD17B10 Q99714 4/20 0.46
THRB P10828 1/20 0.46
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
CYP3A4 P08684 2/20 0.44
TSHR P16473 2/20 0.44
CYP1A1 P04798 2/20 0.44
CYP1B1 Q16678 2/20 0.44
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 5/20 0.40
POLB P06746 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27705873 0.84 CYP1A2 (0.52) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL2928914 0.83 KMT2A (0.56) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL975512 0.82 CYP1A2 (0.53) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL9976124 0.80 CYP1A2 (0.52) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL7665539 0.80 CYP1A2 (0.52) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL7658846 0.80 CYP1A2 (0.52) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL15327502 0.79 CYP1A2 (0.47) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL22493918 0.78 TDP1 (0.56) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL2306938 0.77 CYP1A2 (0.48) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL14562137 0.77 CYP1A2 (0.44) CYP1A2ERBB2FYNMAOAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106075437-B A kind of preparation method of the nuclear shell structure drug carrier of near infrared light excitation real time monitoring drug release 哈尔滨工业大学 2019-03-29 CN claimed
CN-106075437-B A kind of preparation method of the nuclear shell structure drug carrier of near infrared light excitation real time monitoring drug release 哈尔滨工业大学 2019-03-29 CN disclosed
EP-1807436-B1 HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF INTEZYNE TECHNOLOGIES INC (US) 2014-06-18 EP disclosed
EP-2502941-A1 Heterobifunctional poly (ethylene glycol) and uses thereof Intezyne Technologies Inc. (US) 2012-09-26 EP disclosed
US-8268936-B2 Synthesis of hybrid block copolymers and uses thereof INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-18 US disclosed
US-20120196989-A1 SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2012-08-02 US disclosed
EP-2348096-A2 Synthesis of hybrid block copolymers and uses thereof Intezyne Technologies Inc. (US) 2011-07-27 EP disclosed
US-20110124840-A1 Synthesis of Homopolymers and Block Copolymers INTEZYNE TECHNOLOGIES, INC. 2011-05-26 US disclosed
US-20110021718-A1 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF INTEZYNE TECHNOLOGIES (US) 2011-01-27 US disclosed
US-7612153-B2 conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents INTEZYNE TECHNOLOGIES, INC. (US) 2009-11-03 US disclosed
EP-2067801-A1 Synthesis of Hybrid Block Copolymers Intezyne Technologies Incorporated (US) 2009-06-10 EP disclosed
EP-1833958-A4 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF INTEZYNE TECHNOLOGIES INC (US) 2009-01-14 EP disclosed
EP-1848460-A2 SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS Intezyne Technologies Incorporated (US) 2007-10-31 EP disclosed
EP-1833958-A2 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF Intezyne Technologies Incorporated (US) 2007-09-19 EP disclosed
EP-1807436-A2 HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF Intezyne Technologies Incorporated (US) 2007-07-18 EP disclosed
WO-2006086325-A2 SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2006-08-17 WO disclosed
US-20060172914-A1 Synthesis of hybrid block copolymers and uses thereof INTEZYNE TECHNOLOGIES, INC. 2006-08-03 US disclosed
WO-2006074202-A2 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2006-07-13 WO disclosed
US-20060142506-A1 Heterobifunctional poly(ethylene glycol) and uses thereof INTEZYNE TECHNOLOGIES, INC. 2006-06-29 US disclosed
WO-2006047419-A2 HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142506-A1 Heterobifunctional poly(ethylene glycol) and uses thereof GNE, ALG1, EPHX2 CYP1A2 2705/4885ERBB2 114/4885FYN 2895/4885
US-20110124840-A1 Synthesis of Homopolymers and Block Copolymers PARG, PCNA, PARN CYP1A2 1901/4885ERBB2 262/4885FYN 906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.